MEM.AU Memphasys Ltd
- Market cap
- AUD 12.4M
- P/E
- -
- P/B
- 2.94x
- ROE
- -97.4%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is MEM.AU undervalued?
Graham numberThe Graham number of Memphasys Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Memphasys Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-97.4%), below 10%.
ROA 0/1
Return on assets (-36.5%) is below the industry median (-36.5%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-11.9%) is below the industry median (12.5%).
Revenue Growth 2/2
Revenue grew 161.2% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (100.7%), above 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (2.9x) is below the industry median (3.2x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Memphasys Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Memphasys Ltd
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In…
Full company profileMemphasys Ltd financial statements
Memphasys Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 211K | 27.1K | 15.4K | 60.0K | 527K | 274K |
| Gross Profit | -20.7K | -21.0K | -8.92K | -196K | -48.0K | -923K | -825K | -1.57M | 431K | -1.52M |
| Operating Income | -2.11M | -1.17M | -1.08M | -1.26M | -1.69M | -1.48M | -3.63M | -5.24M | -2.57M | -4.15M |
| EBITDA | -1.75M | -103K | -988K | -869K | -1.14M | -1.39M | -2.36M | -4.24M | -2.57M | -3.56M |
| Net Income | -2.00M | -401K | -1.04M | -1.13M | -1.49M | -2.08M | -3.40M | -4.44M | -4.94M | -4.10M |
| EPS | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 7.30M | 4.22M | 6.84M | 11.3M | 14.6M | 14.1M | 14.7M | 12.4M | 11.0M | 11.2M |
| Total Liabilities | 7.70M | 866K | 765K | 1.54M | 5.97M | 6.47M | 7.28M | 5.59M | 5.65M | 7.02M |
| Shareholders' Equity | -402K | 3.35M | 6.07M | 9.76M | 8.61M | 7.65M | 7.38M | 6.84M | 5.37M | 4.21M |
| Cash & Short-term Investments | 3.83M | 202K | 874K | 2.01M | 2.00M | 312K | 681K | 278K | 298K | 1.18M |
| Total Debt | 6.74M | 482K | 6.75K | 1.07M | 5.36M | 5.56M | 6.37M | 4.81M | 5.11M | 4.24M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.23M | -738K | -707K | 120K | 44.7K | 312K | -1.41M | -3.23M | -2.41M | -2.49M |
| Capital Expenditure | 665K | 2.41K | 13.7K | 3.14M | 3.00M | 2.92M | 1.82M | 638K | 4.00 | 3.38K |
| Free Cash Flow | -1.89M | -741K | -721K | -3.02M | -2.96M | -2.61M | -3.23M | -3.87M | -2.41M | -2.49M |
| Ratios | ||||||||||
| ROE | - | -12.0% | -17.2% | -11.6% | -17.3% | -27.2% | -46.1% | -65.0% | -92.1% | -97.4% |
| ROA | -27.4% | -9.5% | -15.3% | -10.0% | -10.2% | -14.7% | -23.2% | -35.7% | -44.8% | -36.5% |
| Net Profit Margin | - | - | - | - | -702.9% | -7,668.9% | -22,136.6% | -7,403.4% | -937.9% | -1,498.7% |
| Debt to Equity | - | 0.14x | 0.00x | 0.11x | 0.62x | 0.73x | 0.86x | 0.70x | 0.95x | 1.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Memphasys Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 849K | 0.00 | - |
| 2022 | AUD 1.09M | 0.00 | - |
| 2021 | AUD 2.97M | 0.00 | - |
| 2020 | AUD 3.77M | 0.01 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 27, 2026.
Who owns Memphasys Ltd
- Insiders 38.86%
- Institutions 0.00%
- Public & others 61.14%
- Shares outstanding 3.10B
- Free float 1.61B
Memphasys Ltd company profile
- Company name
- Memphasys Ltd
- Ticker
- MEM.AU
- ISIN
- AU000000MEM5
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Fiscal year end
- June
- Address
- 34-36 Richmond Road, Homebush, NSW, Australia, 2140
- Phone
- 61 2 8415 7300
- Website
- memphasys.com
About Memphasys Ltd
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Memphasys Ltd management
3- Mr. David Raymond Tasker B.Com.Executive Chairman
- Prof. R. John Aitken Ph.D., ScD FRSEScientific Director
- Mr. Stefan RossCompany Secretary